3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Phase 2
3
Phase 1/2
2
Phase EARLY_PHASE1
1
Status
Completed
3
Terminated
1
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
4
Sponsor
Cancer Type
Genitourinary
4
Conditions
Prostatic Neoplasms
1
Prostate Cancer Non-Metastatic
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Interventions
Cisplatin
187
Carboplatin
182
Paclitaxel
177
Docetaxel
145
Cyclophosphamide
129
Dexamethasone
117
pembrolizumab
106
Doxorubicin
103
Bevacizumab
103
Gemcitabine
102
Rituximab
96
Prednisone
87
Fluorouracil
86
Pemetrexed
82
Radiotherapy
77
Vincristine
71
Etoposide
71
Capecitabine
69
Nivolumab
68
Trastuzumab
67
Leucovorin
64
Cytarabine
57
Methotrexate
52
Oxaliplatin
49
atezolizumab
48
Lenalidomide
43
Ipilimumab
40
Filgrastim
40
Bortezomib
39
Sorafenib
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 3
×
Has results
×
darolutamide
×
Clear all
NCT04736199
2026-02-27
ARANOTE
Bayer
Phase 3
Completed
669 enrolled
16 charts
NCT02799602
2025-12-04
ARASENS
Bayer
Phase 3
Completed
1,306 enrolled
25 charts
2 FDA
NCT04237584
2022-10-07
ESCALATE
MANA RBM
Phase 3
Terminated
23 enrolled
11 charts
NCT02200614
2022-06-28
ARAMIS
Bayer
Phase 3
Completed
1,509 enrolled
13 charts
1 FDA